Search Result

Results for "

C terminus

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Amyloid-β (1) ATP Synthase (1) Bacterial (1) Biochemical Assay Reagents (1) Casein Kinase (1) Complement System (3) Cytochrome P450 (1) Gap Junction Protein (2) GCGR (2) Guanylate Cyclase (1) iGluR (2) MARCKS (1) Mitochondrial Metabolism (1) Na+/K+ ATPase (2) Neurokinin Receptor (2) Neuropeptide Y Receptor (3) p97 (1) PD-1/PD-L1 (1) Phosphatase (1) PIN1 (1) PKC (1) Polo-like Kinase (PLK) (1) PSMA (1) Ser/Thr Protease (1) STAT (1) Thyroid Hormone Receptor (1)
By Research Areas:	Cancer (3) Cardiovascular Disease (3) Endocrinology (1) Infection (1) Inflammation/Immunology (5) Metabolic Disease (3) Neurological Disease (10)

By Targets:

Amyloid-β (1)

ATP Synthase (1)

Bacterial (1)

Biochemical Assay Reagents (1)

Casein Kinase (1)

Complement System (3)

Cytochrome P450 (1)

Gap Junction Protein (2)

GCGR (2)

Guanylate Cyclase (1)

iGluR (2)

MARCKS (1)

Mitochondrial Metabolism (1)

Na+/K+ ATPase (2)

Neurokinin Receptor (2)

Neuropeptide Y Receptor (3)

p97 (1)

PD-1/PD-L1 (1)

Phosphatase (1)

PIN1 (1)

PKC (1)

Polo-like Kinase (PLK) (1)

PSMA (1)

Ser/Thr Protease (1)

STAT (1)

Thyroid Hormone Receptor (1)

By Research Areas:

Cancer (3)

Cardiovascular Disease (3)

Endocrinology (1)

Infection (1)

Inflammation/Immunology (5)

Metabolic Disease (3)

Neurological Disease (10)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P3102

GLP-1(32-36)amide	GCGR	Metabolic Disease
GLP-1(32-36)amide, a pentapeptide, derived from the C terminus of the glucoregulatory hormone GLP-1. GLP-1(32-36)amide could inhibit weight gain and modulate whole body glucose metabolism in diabetic mice .

HY-P1505A

C3a (70-77) (TFA) 1 Publications Verification Complement 3a (70-77) (TFA)	Complement System	Inflammation/Immunology
C3a (70-77) TFA (Complement 3a (70-77) TFA) is an octapeptide corresponding to the COOH terminus of C3a, exhibits the specificity and 1 to 2% biologic activities of C3a .

HY-P1884

LL-37, acetylated,amidated	Bacterial	Infection
LL-37, acetylated, amidated is a cathelicidin peptide LL-37 acetylated on the N-terminus and amidated on the C-terminus. The single human cathelicidin peptide LL-37 has antimicrobial and anti-biofilm activity against multiple Gram-positive and Gram-negative human pathogens, and has wound-healing effects on the host .

HY-P3102A

GLP-1(32-36)amide TFA	GCGR	Metabolic Disease
GLP-1(32-36)amide TFA, a pentapeptide, derived from the C terminus of the glucoregulatory hormone GLP-1. GLP-1(32-36)amide TFA could inhibit weight gain and modulate whole body glucose metabolism in diabetic mice .

HY-P99963

Sudubrilimab HS636	PD-1/PD-L1	Cancer
Sudubrilimab (HS636) is an Ig G1-kappa monoclonal antibody against PDL1. Sudubrilimab is fused at the C terminus of the heavy chain to a TGF-β1 receptor Ⅱ ectodomain (TGFBR2-ECD), and which can sequester the PD-1/PD-L1 pathway and TGF-β bioactivity in the immunosuppressive tumor microenvironment .

HY-P1505

C3a (70-77) Complement 3a (70-77)	Complement System	Inflammation/Immunology
C3a (70-77) is an octapeptide corresponding to the COOH terminus of C3a, exhibits the specificity and 1 to 2% biologic activities of C3a.

HY-P1735

Moth Cytochrome C (MCC) (88-103)	Cytochrome P450	Inflammation/Immunology
Moth Cytochrome C (MCC) (88-103), derived from the carboxyl terminus of moth cytochrome c, induces positive selection of TCR transgenic thymocytes .

HY-160550

DPM-1003	Phosphatase	Inflammation/Immunology
DPM-1003 is a PTP1B conformational inhibitor that targets the non-catalytic, disordered segment at the C-terminus of the PTP1B protein, showing improvement in lung inflammation in mice .

HY-P2019

Levitide	Neuropeptide Y Receptor	Neurological Disease
Levitide is a neurohormone-like peptide, can be isolated from skin secretions of the South African frog Xenopus laevis. Levitide comes from preprolevitide, is 88 residues long and contains contains the levitide peptide at the C terminus (Glu-Gly-Met-Ile-Gly-Thr-Leu-Thr-Ser-Lys-Arg-Ile-Lys-Gln-NH2) and the putative signal sequence at the N terminus .

HY-P3891

Substance P (4-11)	Neurokinin Receptor	Neurological Disease
Substance P (4-11), the C-terminus fragment of Substance P (Substance P (HY-P0201)), is a Substance P agonist that shows highly selective for NK1 receptors .

HY-P10247

Amyloid precursor C-terminal peptide	Mitochondrial Metabolism	Neurological Disease
Amyloid precursor C-terminal peptide is cleaved from the C-terminus of Amyloid Precursor Protein (APP). Amyloid precursor C-terminal peptide accumulation causes mitochondrial morphology alteration and basal mitophagy failure, which indicates that amyloid precursor protein C-terminal peptide may correspond to an etiological trigger of Alzheimer’s disease (AD) pathology .

HY-P10055

PSMA targeting peptide PSMA-1	PSMA	Cancer
PSMA-1 is a PSMA targeting peptide (GRFLTGGTGRLLRIS) and can be used for for targeted delivery of glucose-regulated protein (GRP)-silencing siRNAs in PCa cells. PSMA-1 is selected and polyarginine sequences R6 or R9 were added at the C terminus to generate the CTPs. FITC labeling of the peptide with an aminohexanoic acid (Ahx) linker at the N terminus produced FITC-PSMA-1, to track PSMA binding on PCa cells .

HY-157508

VCP Activator 1 1 Publications Verification	p97	Others
VCP Activator 1 is a VCP activator that dose-dependently stimulates VCP ATPase activity. VCP Activator 1 binds an allosteric pocket near the C-terminus. In addition, VCP Activator 1 binding site can also be occupied by a phenylalanine residue in the VCP C-terminal tail .

HY-P10161

Ac-DMQD-pNA	Biochemical Assay Reagents	Others
Ac-DMQD-pNA is a peptide substrate. Both of the recombinant CgCaspase-1 (rCgCaspase-1) and the C-terminus of CgCaspase-1 (rCgCaspase-1-C) exhibits similar caspase activity towards proteolytic substrate Ac-DMQD-pNA and Ac-DEVD-pNA (HY-P1006) .

HY-P5506

C5a Receptor agonist, W5Cha	Complement System	Others
C5a Receptor agonist, W5Cha (Peptide 1) is a selective complement C5a receptor (C5aR) agonist (EC₅₀=0.2 μM), a hexapeptide derived from the C-terminus of *C5a* with specific amino acid modifications. C5a Receptor agonist, W5Cha is able to interact with the Arg-206 site of the C5a receptor through its C-terminal arginine, thereby activating the receptor .

HY-P3932

[Sar4] Substance P (4-11)	Neurokinin Receptor	Neurological Disease
[Sar4] Substance P (4-11) is an analog of Substance P (4-11). Substance P (4-11), the C-terminus fragment of Substance P (Substance P (HY-P0201)), is a Substance P agonist .

HY-131800

3'-Deoxy-3'-amino-ATP	ATP Synthase	Metabolic Disease
3'-Deoxy-3'-amino-ATP, an ATP analogue, is a potent and competitive inhibitor of ATP, with a K_i of 2.3 μM. 3'-Deoxy-3'-amino-ATP can be used to synthesis of 3′-Amino-3′-deoxy transfer RNA by incorporation into the 3' terminus of tRNA-C-C .

HY-P10909

Canvuparatide MBX 2109	Thyroid Hormone Receptor	Endocrinology
Canvuparatide (MBX 2109) is a prodrug for parathyroid hormone (PTH) peptide that releases the bioactive PTH[1-32] peptide agonist that retains a fatty acylated lysine (Lys33) at the C-terminus, thereby extending the halflife of Canvuparatide. Canvuparatide can be used for the symptoms of hypoparathyroidism such as hypocalcemia and hyperphosphatemia .

HY-P1565

Transdermal Peptide Disulfide TD 1 Disulfide(peptide)	Na+/K+ ATPase	Inflammation/Immunology
Transdermal Peptide Disulfide (TD 1 Disulfide(peptide)) is a 11-amino acid peptide, binds toNa ⁺/K ⁺-ATPase beta-subunit (ATP1B1), and mainly interacts with the C-terminus of ATP1B1. Transdermal Peptide Disulfide can enhance the transdermal delivery of many macromolecules .

HY-P3624

Cenderitide	Guanylate Cyclase	Cardiovascular Disease
Cenderitide is a potent agonist of particulate guanylyl cyclase receptor (pGC). Cenderitide is a natriuretic peptide (NP) composed of C-type natriuretic peptide (CNP) fused to the C-terminus of Dendroaspis natriuretic peptide (DNP). Cenderitide activates both pGC-A and pGC-B, activates the second messenger cGMP, suppresses aldosterone, and preserves GFR without reducing blood pressure. Cenderitide can be used for heart failure research .

HY-P1565A

Transdermal Peptide Disulfide TFA TD 1 Disulfide(peptide) TFA	Na+/K+ ATPase	Others
Transdermal Peptide Disulfide TFA (TD 1 Disulfide(peptide) TFA) is a 11-amino acid peptide, binds to Na ⁺/K ⁺-ATPase beta-subunit (ATP1B1), and mainly interacts with the C-terminus of ATP1B1. Transdermal Peptide Disulfide TFA can enhance the transdermal delivery of many macromolecules .

HY-P3815

Casein Kinase 2 Substrate Peptide 1 Publications Verification	Casein Kinase	Others
Casein Kinase 2 Substrate Peptide is a common CK2 substrate peptide. Casein Kinase 2 Substrate Peptide is synthesized with its C-terminus conjugated to 5-[(2-aminoethyl)amino]naphthalene-1-sulfonic acid (EDANS). Casein Kinase 2 Substrate Peptide can be used for protein kinase CK2 activity determination .

HY-P1195

PDZ1 Domain inhibitor peptide	iGluR	Neurological Disease
PDZ1 Domain inhibitor peptide, a cyclic peptide, incorporates a β-Ala lactam side chain linker and targets the PDZ1 domains of the postsynaptic density protein 95 (PSD-95). PDZ1 Domain inhibitor peptide disrupts the GluR6/PSD-95 interaction and is very efficient in competing against the C terminus of GluR6 for the PDZ1 domain .

HY-P5439

Epsilon-V1-2, Cys-conjugated	PKC MARCKS	Others
Epsilon-V1-2, Cys-conjugated is a biological active peptide. (This peptide is the εPKC specific inhibitor. Its inhibitory activity is based on εPKC translocation and MARCKS phosphorylation. This peptide interferes with εPKC interaction with the anchoring protein εRACK. This peptide contains a cysteine residue added to the C-terminus for potential S-S bond formation with a carrier protein.Pyroglutamyl (pGlu) peptides may spontaneously form when either Glutamine (Q) or Glutamic acid (E) is located at the sequence N-terminus. The conversion of Q or E to pGlu is a natural occurrence and in general it is believed that the hydrophobic γ-lactam ring of pGlu may play a role in peptide stability against gastrointestinal proteases. Pyroglutamyl peptides are therefore considered a normal subset of such peptides and are included as part of the peptide purity during HPLC analysis.)

HY-P1136

Gap19	Gap Junction Protein	Cardiovascular Disease
Gap19, a peptide derived from nine amino acids of the Cx43 cytoplasmic loop (CL), is a potent and selective connexin 43 (Cx43) hemichannel blocker. Gap19 inhibits hemichannels caused by preventing intramolecular interactions of the C-terminus (CT) with the CL. Gap19 is not blocking GJ channels or Cx40/pannexin-1 hemichannels. Gap19 has protective effects against myocardial .

HY-P1195A

PDZ1 Domain inhibitor peptide TFA	iGluR	Neurological Disease
PDZ1 Domain inhibitor peptide TFA, a cyclic peptide, incorporates a β-Ala lactam side chain linker and targets the PDZ1 domains of the postsynaptic density protein 95 (PSD-95). PDZ1 Domain inhibitor peptide TFA disrupts the GluR6/PSD-95 interaction and is very efficient in competing against the C terminus of GluR6 for the PDZ1 domain .

HY-108717B

Proteinase K (NGS grade) Protease K (NGS grade)	Ser/Thr Protease	Others
Proteinase K (Protease K) (NGS grade) (EC 3.4.21.64) is a serine protease with high enzyme activity and broad substrate specificity. Proteinase K can preferentially decompose ester bonds and peptide bonds adjacent to the C-terminus of hydrophobic amino acids, sulfur-containing amino acids, and aromatic amino acids, and is often used to degrade proteins to produce short peptides. This product is NGS grade, no Nickase residue, and nucleic acid residue ≤5pg/mg .

HY-P1136A

Gap19 TFA 4 Publications Verification	Gap Junction Protein	Cardiovascular Disease
Gap19 TFA, a peptide derived from nine amino acids of the Cx43 cytoplasmic loop (CL), is a potent and selective connexin 43 (Cx43) hemichannel blocker. Gap19 TFA inhibits hemichannels caused by preventing intramolecular interactions of the C-terminus (CT) with the CL. Gap19 TFA is not blocking GJ channels or Cx40/pannexin-1 hemichannels. Gap19 TFA has protective effects against myocardial .

HY-P991073

MEDI-1814	Amyloid-β	Neurological Disease
MEDI-1814 is a fully human IgG1 antibody that targets the C terminus of Aβ42. MEDI-1814 binds to and sweeps away the circulated Aβ peptides, hence, restricting them from aggregating into toxic oligomers. MEDI-1814 can be used for the study of Alzheimer's diseases. The isotype control for MEDI-1814 can refer to Human IgG1 kappa, Isotype Control (HY-P99001) .

HY-P1321

GR231118 1229U91; GW1229	Neuropeptide Y Receptor	Neurological Disease
GR231118, an analogue of the C-terminus of neuropeptide Y, is a potent , competitive and relative seletive antagonist at human neuropeptide Y Y receptor with a pK_i of 10.4. GR231118 a potent agonist at the human neuropeptide Y Y4 receptor (pEC₅₀=8.6; pK_i=9.6) and a weak agonist at the human and rat neuropeptide YY2 and Y5 receptors. GR231118 also has high affinity for the mouse neuropeptide Y Y6 receptor (pK_i= 8.8) .

HY-P1321A

GR231118 TFA 1229U91 TFA; GW1229 TFA	Neuropeptide Y Receptor	Neurological Disease
GR231118 TFA, an analogue of the C-terminus of neuropeptide Y, is a potent , competitive and relative seletive antagonist at human neuropeptide YY receptor with a pK_i of 10.4. GR231118 a potent agonist at the human neuropeptide YY4 receptor (pEC₅₀=8.6; pK_i=9.6) and a weak agonist at the human and rat neuropeptide Y Y2 and Y5 receptors. GR231118 also has high affinity for the mouse neuropeptide YY6 receptor (pK_i= 8.8) .

HY-12135

Poloxipan	Polo-like Kinase (PLK) PIN1 STAT	Cancer
Poloxipan is a pan-specific polo-like kinase (PLK) inhibitor that can inhibit a non-catalytic region at the C-terminus called the Polo-box domain (PBD) found in kinases. The IC₅₀ values for Poloxipan against the PBDs of PLK-1/2/3 are 3.2 μM, 1.7 μM, and 3.0 μM, respectively. Poloxipan also inhibits other phospho-tyrosine binding domains, such as the forkhead-associated (FHA) domain of CHK-2, the WW domain of peptidyl-prolyl cis/trans isomerase (PIN1), and the phospho-tyrosine binding domains of STAT1/3/5 and lymphocyte-specific protein tyrosine kinase's SH2 domain. Poloxipan can be used in cancer research .

Cat. No.	Product Name	Target	Research Area